Cargando…

Efficacy and safety of tripterygium wilfordii multiglycosides in idiopathic membranous nephropathy: Protocol for an open-label randomized controlled clinical trial

OBJECTIVE: Tripterygium wilfordii multiglycosides has been demonstrated to be effective in reducing proteinuria and alleviate edema in patients with chronic kidney disease. We aim to evaluate its efficacy and safety in idiopathic membranous nephropathy. METHODS AND ANALYSIS: This is an randomized, o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Geng, Chanyu, Li, Qiang, Pu, Lei, Yang, Hongling, Li, Guisen, Feng, Yunlin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	5200
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8830847/ https://www.ncbi.nlm.nih.gov/pubmed/35147131 http://dx.doi.org/10.1097/MD.0000000000028842

Ejemplares similares

Comparison of tripterygium wilfordii multiglycosides and tacrolimus in the treatment of idiopathic membranous nephropathy: a prospective cohort study
por: Liu, Shanshan, et al.
Publicado: (2015)

Calcineurin inhibitor therapy in combination with Tripterygium wilfordii polyglycoside tablets for idiopathic membranous nephropathy: A retrospective clinical observation
por: Gao, Ying, et al.
Publicado: (2021)

Tripterygium wilfordii multiglycosides combined with prednisone in the treatment of idiopathic membranous nephropathy: A protocol for a systematic review and meta-analysis
por: Jin, Yuxia, et al.
Publicado: (2020)

The effect and safety of low-dose Tripterygium wilfordii in patients with type 2 diabetic nephropathy: A meta-analysis
por: Chen, Yixuan, et al.
Publicado: (2022)

Proteomics analysis reveals novel insights into the mechanism of hepatotoxicity induced by Tripterygium wilfordii multiglycoside in mice
por: Miao, Yingying, et al.
Publicado: (2022)

Review of molecular biological research on the treatment of membranous nephropathy with Tripterygium glycosides based on TCM theory
por: Xu, Pengyu, et al.
Publicado: (2023)

Therapeutic effect of Tripterygium wilfordii Hook F multiglycosides on gut barrier dysfunction in rats with acute necrotizing pancreatitis
por: WANG, JIE, et al.
Publicado: (2013)

Retrospective analysis of tacrolimus combined with Tripterygium wilfordii polyglycoside for treating idiopathic membranous nephropathy
por: Shang, Shun-Lai, et al.
Publicado: (2018)

Mechanism of action of Tripterygium wilfordii for treatment of idiopathic membranous nephropathy based on network pharmacology
por: Shi, Honghong, et al.
Publicado: (2022)

Astragalus membranaceus formula for moderate-high risk idiopathic membranous nephropathy: A meta-analysis
por: Wang, Dan, et al.
Publicado: (2023)

Comparison of cyclophosphamide and calcineurin inhibitors for idiopathic membranous nephropathy: A protocol for systematic review and meta-analysis
por: Li, Kang, et al.
Publicado: (2022)

Efficacy and safety of Tripterygium wilfordii multiglucoside for idiopathic membranous nephropathy: a systematic review with bayesian meta-analysis
por: Wang, Hongyun, et al.
Publicado: (2023)

A nomogram prediction model for treatment failure in primary membranous nephropathy
por: Geng, Chanyu, et al.
Publicado: (2023)

Idiopathic membranous nephropathy in a patient diagnosed with IgG4-related disease: A case report
por: Ma, XiaoYing, et al.
Publicado: (2020)

Chinese medicinal herbs for idiopathic membranous nephropathy in adults with nephrotic syndrome: A systematic review of effectiveness and safety
por: Liu, Meifang, et al.
Publicado: (2021)

Efficacy and safety of tacrolimus monotherapy versus tacrolimus-corticosteroid combination therapy for idiopathic membranous nephropathy: A meta-analysis
por: Gong, Lifeng, et al.
Publicado: (2021)

Clinicopathologic characteristic and prognosis in idiopathic membranous nephropathy patients with focal segmental sclerosis lesion: A retrospective observational study
por: Cheng, Wenrong, et al.
Publicado: (2021)

Efficacy and safety of tacrolimus monotherapy versus cyclophosphamide–corticosteroid combination therapy for idiopathic membranous nephropathy: A meta-analysis
por: Gong, Lifeng, et al.
Publicado: (2021)

Effect of Cordyceps sinensis and Tripterygium wilfordii polyglycosidium on podocytes in rats with diabetic nephropathy
por: HAO, LI, et al.
Publicado: (2014)

Prediction Models of Primary Membranous Nephropathy: A Systematic Review and Meta-Analysis
por: Geng, Chanyu, et al.
Publicado: (2023)

Membranous nephropathy in a patient with ankylosing spondylitis: A case report
por: Chen, Ruiying, et al.
Publicado: (2017)

Molecular mechanism of Cuscutae semen–radix rehmanniae praeparata in relieving reproductive injury of male rats induced with tripterygium wilfordii multiglycosides: A tandem mass tag-based proteomics analysis
por: Han, Shanshan, et al.
Publicado: (2023)

Study of the Active Components and Molecular Mechanism of Tripterygium wilfordii in the Treatment of Diabetic Nephropathy
por: Wang, Lin, et al.
Publicado: (2021)

Patients With Combined Membranous Nephropathy and Focal Segmental Glomerulosclerosis Have Comparable Clinical and Autoantibody Profiles With Primary Membranous Nephropathy: A Retrospective Observational Study
por: Gu, Qiu-hua, et al.
Publicado: (2016)

Clinical Features and Outcomes in Patients With Membranous Nephropathy and Crescent Formation
por: Wang, Jia, et al.
Publicado: (2015)

Efficacy and safety of rituximab in the treatment of membranous nephropathy: A systematic review and meta-analysis
por: Lu, WanJun, et al.
Publicado: (2020)

Tacrolimus-induced epilepsy with primary membranous nephropathy: A case report
por: Yang, Yan, et al.
Publicado: (2021)

HLA-DR, and not PLA2R, is expressed on the podocytes in kidney allografts in de novo membranous nephropathy
por: Wen, Jiqiu, et al.
Publicado: (2016)

Clinical Practice Guideline for Tripterygium Glycosides/Tripterygium wilfordii Tablets in the Treatment of Rheumatoid Arthritis
por: Lin, Na, et al.
Publicado: (2021)

Clinical observation on the effect of Wuzhi soft capsule on FK506 concentration in membranous nephropathy patients
por: Zhang, Zhu, et al.
Publicado: (2019)

Mechanistic analysis for the origin of diverse diterpenes in Tripterygium wilfordii
por: Tu, Lichan, et al.
Publicado: (2022)

Membranous Nephropathy Associated With Immunological Disorder-Related Liver Disease: A Retrospective Study of 10 Cases
por: Dauvergne, Maxime, et al.
Publicado: (2015)

Based on Network Pharmacology Tools to Investigate the Mechanism of Tripterygium wilfordii Against IgA Nephropathy
por: Xia, Ming, et al.
Publicado: (2021)

Lipoprotein glomerulopathy resulting from compound heterogeneous mutations of APOE gene: A case report
por: Li, Yunsi, et al.
Publicado: (2022)

Native Endophytes of Tripterygium wilfordii-Mediated Biotransformation Reduces Toxicity of Celastrol
por: Ma, Ping-yang, et al.
Publicado: (2022)

The genome of Tripterygium wilfordii and characterization of the celastrol biosynthesis pathway
por: Pei, Tianlin, et al.
Publicado: (2021)

Tripterygium Wilfordii inhibits tonsillar IgA production by downregulating IgA class switching in IgA nephropathy
por: Li, Huining, et al.
Publicado: (2017)

Primary Sjögren syndrome-associated acute interstitial nephritis and type 3 renal tubular acidosis in a patient with thin basement membrane nephropathy: A case report
por: Du, Tian, et al.
Publicado: (2020)

Low dose sacubitril/valsartan is effective and safe in hemodialysis patient with decompensated heart failure and hypotension: A case report
por: Feng, Yunlin, et al.
Publicado: (2022)

Retrospective analysis of Tripterygium wilfordii polyglycoside combined with angiotensin receptor blockers for the treatment of primary membranous nephropathy with sub-nephrotic proteinuria
por: Guo, Yuanyuan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_sgj02paln9hgsjp276h249qtps